Uproleselan did not significantly improve overall survival in the intent-to-treat population of relapsed/refractory AML patients. Primary refractory AML patients showed a substantial survival benefit ...

Monitoring and treating heart failure (HF) is a challenging condition at any age. Several models, such as Atrial fibrillation, Hemoglobin, Elderly, Abnormal renal parameters, Diabetes mellitus (AHEAD) ...

Long-term human albumin therapy failed to significantly improve long-term survival outcomes in cirrhotic patients with acute decompensation and ascites, the phase III randomized PRECIOSA trial showed.

The first day after infrastructure fails is when most people make the moves they regret later. Not because they’re... The post What survival experts say matters most in the first day after ...

Major trial finds immediate or high-dose TB treatment does not lower overall mortality in HIV-related sepsis, except in ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

New research across seven global biobanks shows that the DNA driving disease onset does not determine survival; instead, lifespan-linked genes and cross-trait scores hold the real clues to prognosis.

Severe alcohol-associated hepatitis (sAH) remains a highly lethal condition with limited therapeutic options. Characterized by rapid liver decompensation, sAH is often accompanied by acute kidney ...

Jan 24 (Reuters) - Merck (MRK.N), opens new tab and Japan-based Eisai (4523.T), opens new tab said on Friday a combination of their therapies failed to extend the lives of patients with a type of ...